Fig. 5: RGS3 knockdown reduces metastasis potential in vivo.

A, B Tumor morphology and weight assessment 7 weeks after intraperitoneal injection of shRGS3 and control OVCAR8 cells. C The expression of RGS3, CD31, vimentin, and N-Cadherin was measured in IOD. D IHC analysis of RGS3, CD31, vimentin, and N-Cadherin expression in RGS3-knockdown tumors. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, (scale bars: 200 μm, 100 μm).